Dr. Rhonda Patrick on health: what the evidence says · JRE #773

What the evidence says 01 / RECORD

Patrick said eight clinical trials led the FDA to add a warning label to ibuprofen specifically because chronic use doubled the risk of both stroke and heart attack. In July 2015 the FDA did strengthen its warning that non-aspirin NSAIDs, a class that includes ibuprofen, naproxen, and diclofenac, can cause heart attack or stroke, but the change applied to the whole drug class rather than to ibuprofen alone, and the FDA and reporting on the decision stated the risk can begin within the first weeks of use, not only with chronic use. That decision drew on evidence including a large meta-analysis of individual participant data from randomized trials, published in The Lancet in 2013 by the Coxib and traditional NSAID Trialists' Collaboration, which pooled data across hundreds of NSAID trials (280 placebo-controlled and 474 head-to-head), not eight. That meta-analysis found high-dose ibuprofen was associated with roughly a doubling of major coronary events specifically (rate ratio 2.22, 95% CI 1.10-4.48, drawn from 22 ibuprofen-comparison trials), but explicitly found no statistically significant increase in stroke risk for any NSAID, and the broader major-vascular-events rate ratio for ibuprofen (1.44, CI 0.89-2.33) was also not statistically significant. So the claim is directionally correct that regulators strengthened NSAID cardiovascular warnings based on accumulated trial evidence, but the eight-clinical-trials count is unsupported (the underlying evidence base ran to the hundreds of trials), the warning covers the NSAID class rather than ibuprofen specifically, and the twofold figure held for major coronary events at high ibuprofen doses but not for stroke or for vascular events overall.